AI and Cancer Research ── 2026-10-03
New papers on cancer and AI, collected from journal feeds, PubMed (searched across all journals) and OpenAlex (a public index used instead of Google Scholar), judged by Jev (an AI that makes language judgements): original research, AI central, which of 13 themes, treatment or trials, and then ranked by importance up to a daily limit. Journals are not filtered by impact factor; each paper shows its journal's IF-equivalent (OpenAlex two-year mean citedness) and the date of that value. Each entry shows the full original abstract.
Read by cancer type: Cancer biology(3) · Breast(1) · Lung(2) · Pancreatic(1) · Prostate(2) · ACC(0) · Brain(0) · Ovarian(0) · Endometrial(1) · Gastric(1) · Liver(2) · Kidney(0) · Bladder(0)
Cancer molecular biology and AI
- Abstract
Although genetic sequencing is routine in cancer care, translating a tumor’s complex mutation profile into actionable treatment decisions remains a central challenge. MutationProjector is pretrained on a large corpus of genomic alterations across more than 30,000 tumors, integrated with extensive molecular knowledge. The resulting projection reveals a tumor’s altered molecular pathways, facilitating model interpretation, and it accurately reconstructs held-out mutations, demonstrating model generalization. When applied to predict immunotherapy or chemotherapy resistance across multiple cancer types and cohorts, MutationProjector achieves or exceeds state-of-the-art performance in all contexts. It identifies unexpected biomarkers, including KMT2D mutation in immunotherapy sensitivity and joint alteration of SMARCA4 and STK11 in immunotherapy resistance. These results establish a unifying framework for connecting tumor genotypes to biological mechanisms and therapeutic outcomes.
Significance: This work describes MutationProjector, a tumor genomic foundation model pretrained on more than 30,000 tumors. It maps mutations to biological states for diagnosis and treatment, achieving state-of-the-art performance in predicting therapy resistance and identifying biomarkers such as KMT2D (sensitivity) and SMARCA4/STK11 coalterations (resistance).
Journal IF-equivalent: 7.7 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Kong J, Lee I, Boecher D, Singhal A, Kelly MR, Moon J, et al. A Foundation Model of Cancer Genotype Enables Precise Predictions of Therapeutic Response. Cancer Discov. 2026 May 26;16(10):2021-36. doi:10.1158/2159-8290.cd-25-1735. PMID: 42188872; PMCID: PMC13367315.Checked: Abstract only - Abstract
Background: Molecular profiling tests currently relies significantly on genomics or transcriptomics analysis, leading a prolonged turnaround time and higher costs procedure. This comprehensive pan-cancer study aims to develop a general, weakly supervised, and clinically interpretable deep learning (DL) approach for predicting large-scale biomarkers directly from hematoxylin and eosin (H&E)-stained whole slide images (WSIs).
Methods: We introduce Rapid and Intelligent Detector for Genetic Estimation (RIDGE) , a deep learning-based artificial intelligence (AI) system for gene expression signatures and standard biomarkers automated prediction in annotation-free whole slide images. RIDGE was developed and validated using 4983 WSIs from 4680 patients across 12 solid tumors from The Cancer Genome Atlas (TCGA). Its feasibility was further confirmed in an external validation cohort of 221 WSIs from 105 colorectal cancer patients from The Clinical Proteomic Tumor Analysis Consortium (CPTAC), specifically for predicting microsatellite instability (MSI) status.
Results: RIDGE achieved an overall area under the curve (AUC) of 0.763 (95% CI, 0.724–0.802) across 12 cancer types. In the external CPTAC cohort, RIDGE demonstrated an AUC of 0.769 (95% CI 0.686–0.841) for MSI status prediction, underscoring its reproducibility. We observed that the morphological visual characteristics could be captured by our model, enabling the gene expression signatures and standard biomarkers highly detectable directly from WSIs.
Conclusions: These findings highlight RIDGE’s potential to significantly expedite cancer screening and personalized therapy. Moreover, RIDGE offers an AI-assisted assessment approach with high predictive performance to elucidate and quantify genotype-phenotype relationships in cancer, demonstrating its promise in advancing the field of cancer diagnostics. Clinical trial number Not applicable.
Journal IF-equivalent: 3.8 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Xi H, Feng X, Lu Y, Li G, Zhang Y, Li J, et al. Deep learning-based large-scale pan-cancer multiple biomarkers prediction using RIDGE with pathological images. BMC Med Imaging. 2026 Sep 30 [Epub ahead of print]. doi:10.1186/s12880-026-02695-4.Checked: Abstract only
See all 3 Cancer biology papers →
Breast cancer: treatment, trials and AI
- Abstract
Background: Accurate noninvasive estimation of pathological complete response (pCR) after neoadjuvant therapy (NAT) in triple-negative breast cancer (TNBC) may support multidisciplinary discussions, but multimodal MRI-ultrasound evidence remains limited. We developed and externally validated a clinicopathological deep learning radiomics nomogram and explored its potential auxiliary value in a strictly hypothetical post-hoc surgical-planning scenario.
Methods: With institutional review-board approval and waived consent, this retrospective multicenter diagnostic accuracy study included 436 biopsy-proven TNBC patients who underwent NAT and surgery: Center 1 training cohort (n = 268) and internal validation cohort (n = 86), plus historical cases from cooperating Centers 2–3 for external validation (n = 82). pCR was defined as ypT0/is ypN0. Pretreatment dynamic contrast-enhanced MRI (DCE-MRI), diffusion-weighted imaging (DWI)/apparent diffusion coefficient (ADC) maps, T2-weighted imaging (T2WI), and B-mode ultrasound were analyzed. Intratumoral and 5-mm peritumoral ring radiomics features were extracted and selected by LASSO. DenseNet-121 extracted modality-specific deep features, fused using multi-head self-attention. Age, tumor size, Ki-67, tumor-infiltrating lymphocytes (TILs), cT/N stage, and histological grade were integrated with imaging scores in a logistic-regression nomogram. Parameters and thresholds were locked after Center 1 development and applied once to external data. No model output was used clinically. Feature standardization and ComBat harmonization parameters were strictly locked to the training cohort before application to validation data. Results pCR occurred in 182/436 patients (41.7%). The nomogram achieved areas under the receiver operating characteristic curve (AUCs) of 0.917 (95% CI, 0.881-0.947) in training, 0.883 (0.814-0.937) in internal validation, and 0.856 (0.773-0.921) in external validation, exceeding clinical (external AUC, 0.721), radiomics (0.786), and deep learning (0.819) models. External sensitivity, specificity, and accuracy at the locked threshold were 0.765, 0.813, and 0.793, respectively. Calibration was acceptable (slope, 0.93; intercept, −0.06; Brier score, 0.16). Decision curve analysis showed net benefit for thresholds of 0.20-0.70. Multi-threshold analysis revealed that a high-specificity threshold (0.65) yielded a positive predictive value of 0.85, potentially identifying a subset of patients with very high confidence of achieving pCR. Compared with the clinical model, external reclassification improved (continuous net reclassification improvement [NRI], 0.34; integrated discrimination improvement [IDI], 0.11; P = 0.003 and P = 0.008, respectively).
Conclusion: Among the few multicenter TNBC studies combining MRI, ultrasound, intratumoral/peritumoral radiomics, and attention-based deep learning, this nomogram showed good retrospective accuracy for pCR prediction after NAT. The model is presented as an aid for pCR prediction and preoperative stratification rather than as direct support for surgical decision-making. Prospective validation and clinical-impact studies are required before implementation.
Journal IF-equivalent: 2.7 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Qi C. A multimodal deep learning radiomics nomogram integrating clinicopathological features for predicting pathological complete response after neoadjuvant therapy in triple-negative breast cancer: a multicenter retrospective study. Front Oncol. 2026 Oct 2;16:1893983. doi:10.3389/fonc.2026.1893983.Checked: Abstract only
Lung cancer: treatment, trials and AI
- Abstract
Background: Postoperative pulmonary complications (PPCs) significantly impair recovery after lung cancer surgery. We developed and validated an ensemble machine learning (ML) model to identify high-risk patients across the perioperative period.
Methods: We retrospectively analyzed data from 3,476 patients undergoing anatomic lung resection between 2016 and 2020 (Cohort 1). Predictors were selected through clinical expertise, statistical significance, and the Boruta algorithm. Seven ML models were developed, with the soft Voting Classifier (integrating Random Forest, CatBoost, and XGBoost) identified as the optimal approach. A prospective temporal validation cohort (n = 171) was also evaluated. Performance was assessed by AUROC with patient-level bootstrap 95% CIs, Brier score, calibration, and decision-curve analysis..
Results: The overall incidence of PPCs was 15.9%. In internal validation, the Voting Classifier ranked highest among eight models for overall PPCs (AUROC 0.7216; 95% CI 0.7044–0.7369), comparable to XGBoost and CatBoost with overlapping confidence intervals, and numerically higher than logistic regression (0.7009). In temporal validation, the model maintained moderate discriminative ability (AUROC 0.6366; 95% CI 0.5179–0.7551). Despite a surgical paradigm shift (VATS from 73.8% to 98.2%), the model retained discriminative ability for postoperative pneumonia (AUROC 0.7434; 95% CI 0.5887–0.8759), the strongest of the three subtype predictions (internal AUROC 0.7799); discrimination was inconclusive for prolonged air leak (0.6790; 0.4673–0.8796) .
Conclusions: The Voting Classifier provides an interpretable tool for predicting PPCs and guiding perioperative risk stratification, enabling targeted interventions for high-risk patients. The model was developed in patients undergoing upfront anatomic lung resection and does not apply to those receiving neoadjuvant therapy Ethical Registration ChiCTR2500102082 on May 8 2025
Journal IF-equivalent: 1.7 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Zhou S, Tian L, Wang X, Ma C, Li S, Cha L, et al. Ensemble Machine Learning for Predicting Postoperative Pulmonary Complications (PPCs) in Lung Surgery: A Prospective Temporal Validation and Clinical Evaluation Study. Current Problems in Surgery. 2026 Oct [Epub ahead of print]. doi:10.1016/j.cpsurg.2026.102191.Checked: Abstract only - Abstract
Background: Anemia represents a frequent and clinically burdensome complication in patients with primary lung cancer receiving platinum-based regimens, yet robust risk stratification tools that integrate multidimensional clinical data and undergo external validation remain scarce. This multicenter study sought to develop and externally validate a machine learning-based predictive model for CIA in this population.
Methods: A total of 3,434 patients with primary lung cancer were retrospectively enrolled from two geographically distinct institutions, with 3,097 assigned to the training/internal validation set (7:3 split) and 337 retained as an independent external validation set. Variables with missing rates exceeding 30% were excluded, and remaining missing data were imputed using multiple imputation by chained equations (MICE). Thirteen candidate predictors were preselected via univariate screening and least absolute shrinkage and selection operator (LASSO) regression. Nine machine learning algorithms were developed and comparatively evaluated using area under the receiver operating characteristic curve (AUC), calibration plots, and decision curve analysis. Model interpretability was achieved through SHapley Additive exPlanations (SHAP). The primary outcome was defined as hemoglobin levels < 100 g/L (CTCAE Grade ≥ 2) recorded during the first two cycles of chemotherapy.
Results: Among the nine candidate models, LightGBM achieved the highest discriminative performance, with AUCs of 0.871 (95% CI: 0.852–0.891) in the training set, 0.797 (95% CI: 0.763–0.831) in internal validation, and 0.684 (95% CI: 0.626–0.742) in the external validation set derived from Linfen Central Hospital. Calibration and decision curve analyses consistently demonstrated superior agreement and net clinical benefit for LightGBM across all three datasets. SHAP-based interpretation identified lymphocyte count, D-dimer, alanine aminotransferase, total bilirubin, sex, and albumin as the six most influential predictors, with D-dimer, female sex, and outpatient admission positively associated with anemia risk, whereas lymphocyte count, liver function indices, and albumin showed inverse associations.
Conclusions: The LightGBM-based model developed herein demonstrates acceptable and moderate predictive performance, satisfactory calibration, and potential clinical utility across geographically diverse populations, offering a preliminary risk-stratification tool for early identification of lung cancer patients at elevated anemia risk prior to chemotherapy initiation. However, given the modest external validation performance, cautious interpretation and further refinement are warranted before widespread clinical deployment.
Journal IF-equivalent: 2.7 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Zhang K, Li X, Zhang X, Wang X, Zhang H, Liu S, et al. Development and validation of a machine learning-based prediction model for anemia risk in patients with primary lung cancer receiving platinum-based chemotherapy: a multicenter study. Front Oncol. 2026 Sep 30;16:1948751. doi:10.3389/fonc.2026.1948751.Checked: Abstract only
Pancreatic cancer: treatment, trials and AI
- Abstract
Neural regulation and an imbalanced immune microenvironment promote Pancreatic ductal adenocarcinoma (PDAC) progression. However, the molecular mechanisms and clinical implications of neuron–tumor interactions remain unclear. We integrated single-cell and spatial transcriptomic data to characterize neuron–tumor interactions in PDAC and classified patients into five innervation subtypes. We then assessed subtype differences in prognosis, immune microenvironment, and genomic instability. In parallel, we developed and externally validated a pathology-based machine learning model for subtype prediction. Finally, functional experiments were performed to investigate the role of a key subtype gene. Single-cell analysis suggested that NEFM-positive neurons exhibited prominent inferred ligand–receptor interactions with PDAC cells. Based on prognosis-associated receptor–ligand pairs derived from this inferred interaction axis, we classified patients with PDAC into five innervation subtypes. These subtypes showed graded differences in prognosis, immune microenvironment, and genomic instability. By integrating histopathological features, we developed and optimized a multiclass model that was externally validated in the XY3-PDAC cohort. This model predicted innervation subtypes and survival with good performance and highlighted key morphological features, improving clinical interpretability and supporting precise PDAC stratification. PTK7 was identified as a key gene in the NICS subtype, and its knockout reduced PDAC cell proliferation and migration and suppressed tumor growth in mice. Single-cell immunotherapy data and multiplex immunofluorescence further showed that PTK7 expression was associated with high M2 macrophage infiltration and low CD8 + T cell infiltration, suggesting a role in immunotherapy resistance. We mapped the molecular landscape of neuron–PDAC regulation and developed a novel receptor–ligand based classification framework to predict prognosis and guide treatment selection for patients with PDAC.
Journal IF-equivalent: 4.0 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Ma J, Xiang W, Yan A, Yang Y, Liu Y, Wang L, et al. Explainable pathomics and multi-omics define PDAC innervation subtypes linked to neuron–tumor crosstalk and immunotherapy response. Biol Direct. 2026 Sep 30 [Epub ahead of print]. doi:10.1186/s13062-026-00995-x.Checked: Abstract only
Prostate cancer: treatment, trials and AI
- Abstract
Skeletal muscle is a major determinant of functional status. The impact of advanced prostate cancer (aPC) systemic therapies on body composition is unknown. We identified aPC patients with serial PET-CTs receiving androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPI), chemotherapy, and/or Lutetium-177. An artificial intelligence algorithm quantified body composition changes from PET-CT images. Linear mixed effects models examined body composition changes over time by treatment type. The algorithm examined 2,342 PET-CTs from 468 patients. On multivariable analysis, ADT was associated with a 9% reduction in muscle density (-1.91 Hounsfield units), ARPIs an additional 6% (-1.4 Hounsfield units), and Lutetium-177 a subsequent 6% (-1.3 Hounsfield units), demonstrating progressive reduction in muscle density across later stages of systemic therapy. This large longitudinal analysis of body composition in aPC patients supports the use of an automated PET-CT algorithm to identify aPC patients on systemic therapy at risk for muscle wasting.
Journal IF-equivalent: 4.5 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Shi C, Wei N, Martinez GM, O’Byrne J, Weston A, Grossardt B, et al. An artificial intelligence algorithm characterizes the deterioration of body composition from systemic therapy for patients with advanced prostate cancer. JNCI: Journal of the National Cancer Institute. 2026 Oct 1 [Epub ahead of print]. doi:10.1093/jnci/djag349.Checked: Abstract only - Abstract
A multimodal artificial intelligence biomarker using prostate tissue images and clinical data predicted long-term outcomes in postprostatectomy patients receiving salvage radiotherapy. The model stratified risk and may help personalize hormone therapy decisions after biochemical recurrence.
Journal IF-equivalent: 1.5 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Morgan TM, Ren Y, Tang S, Zwerink W, Chen E, Mitani A, et al. Development and Validation of a Multimodal Artificial Intelligence–derived Digital Pathology–based Biomarker Predicting Metastasis Among Patients with Biochemical Recurrence After Radical Prostatectomy in NRG/RTOG Trials. Eur Urol. 2025 Dec [Epub ahead of print]. doi:10.1016/j.eururo.2025.12.007. PMID: 41436315; PMCID: PMC12774449.Checked: Abstract only
Adenoid cystic carcinoma: treatment, trials and AI
No new qualifying paper for this issue.
Brain tumours: treatment, trials and AI
No new qualifying paper for this issue.
Ovarian cancer: treatment, trials and AI
No new qualifying paper for this issue.
Endometrial cancer: treatment, trials and AI
- Abstract
To develop a multiparametric MRI-based fusion model integrating habitat radiomics with a Vision Transformer (ViT) to preoperatively predict p53 status in endometrial cancer (EC), and to explore its potential prognostic relevance. From three centers, this retrospective study analyzed 1,230 patients with EC, assigned to a training cohort ( n = 447), an internal validation cohort ( n = 192), and two external validation cohorts ( n = 246 and 345). We used the tumor and habitat regions to extract radiomics features. Deep learning (DL) features were extracted using the ViT model. Clinical, radiomics, habitat, ViT, and fusion models were constructed based on the support vector machine algorithm. Interpretability was enhanced using SHapley Additive Explanations (SHAP) analysis, and prognostic value for progression-free survival (PFS) was further evaluated. p53-abnormal (p53abn) immunophenotype was identified in 232 patients (18.9%). The maximum tumor diameter and histologic grade were selected as clinical predictors of p53abn status. The habitat model attained areas under the curve (AUCs) of 0.770–0.802 in the validation cohorts, outperforming the radiomics model. A fusion model integrating the habitat radiomics and DL features with clinical predictors achieved the optimal performance, with AUCs of 0.881, 0.869, and 0.904 in the internal and two external validation cohorts, respectively. SHAP analysis indicated that the habitat and DL features made significant contributions to p53abn EC prediction. Exploratory survival analysis showed that fusion-model–predicted p53 status was independently associated with PFS. The fusion model may serve as a complementary imaging tool for preoperative assessment of p53 status in EC.
Journal IF-equivalent: 5.3 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Lin G, Chen W, Yang D, Xu L, Cao J, Xia S, et al. Multiparametric MRI-based habitat radiomics integrated with a vision transformer for preoperative prediction of p53 status in endometrial cancer. Cancer Imaging. 2026 Oct 1 [Epub ahead of print]. doi:10.1186/s40644-026-01133-6.Checked: Abstract only
See all 1 Endometrial papers →
Gastric cancer: treatment, trials and AI
- Abstract
Early gastric cancer (EGC) typically carries a favorable prognosis, and many patients can achieve curative outcomes through local resection when lymph node metastasis (LNM) is absent. Therefore, reliable preoperative evaluation of perigastric LNM is essential for guiding individualized treatment decisions. This study aimed to establish an accurate deep learning model for predicting LNM in EGC using biopsy slides and to investigate the pathological and microenvironmental features that underlie the model’s predictive behavior. T1-stage gastric cancer patients from multiple centers with pathologically confirmed LNM status after D2 lymphadenectomy were included. H&E-stained biopsy slides were used to train deep learning models, and three high-performing models (ViTamin, ConvNeXt V2, Swin Transformer V2) were integrated into an ensemble model, LMRNet. Its performance was evaluated using multicenter cohorts. Additionally, a dual Swin Transformer classifier and HoVer-Net were employed to characterize histopathological subtypes and tumor microenvironment (TME) features, allowing interpretation of the histopathological and microenvironmental patterns associated with model predictions. A total of 660 patients were enrolled. LMRNet achieved AUCs of 0.947 in the internal biopsy cohort and 0.900 in the external biopsy cohort, demonstrating high accuracy. In multicenter surgical cohorts, performance remained stable with AUCs ranging from 0.768 to 0.894. The subtype classifier showed strong agreement with TCGA annotations and revealed that diffuse-type regions were associated with higher LNM risk. TME analysis demonstrated that patches enriched with inflammatory cells, particularly those in close spatial proximity to tumor cells, received significantly higher LNM risk. Regions where stromal cells formed structural barriers between tumor and inflammatory cells were assigned lower risk. These findings highlight specific morphological and cellular interaction patterns captured by LMRNet. LMRNet provides accurate and generalizable LNM prediction based on biopsy slides. By integrating subtype and TME analyses, the study uncovers morphological correlates of predicted metastatic risk in EGC.
Journal IF-equivalent: 8.3 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Lin Q, Liu Y, He J, Ruan R, Guan T, Zhang Z, et al. LMRNet: a biopsy-derived deep learning model for predicting lymph node metastasis in early gastric cancer with pathological interpretability. J Transl Med. 2026 Oct 1 [Epub ahead of print]. doi:10.1186/s12967-026-08966-6.Checked: Abstract only
Liver cancer: treatment, trials and AI
- Abstract
Purpose: To develop HepaKineticNet, a deep learning framework that models inter-phase kinetic dynamics on multi-phase contrast-enhanced CT (CECT) to generate intratumoral heterogeneity (ITH) maps, and to assess in an independent external cohort whether a clinical–radiomics fusion model improves overall survival (OS) prediction in BCLC stage B–C hepatocellular carcinoma (HCC) treated with locoregional therapy plus first-line TKI and anti–PD-1 agents.
Patients and Methods: In this bi-institutional retrospective study, HepaKineticNet was developed using 359 patients from one institution (231 training, 128 validation) and evaluated in an independent external test cohort of 95 patients from a second institution. HepaKineticNet integrates a Spatial Kinetic Differential Attention module into an nnU-Net backbone, separately encoding arterial wash-in and delayed wash-out kinetics, with multiscale coefficient-of-variation self-supervision. Ten radiomics features (hierarchical filtering) and three clinical variables selected by LASSO-penalised Cox regression (10-fold cross-validation) were used to build clinical, radiomics, and fusion Cox models.
Results: A total of 277 deaths occurred, 128 of them in the development cohort. Baseline characteristics were balanced (all P> 0.05). In the external test cohort, the fusion model achieved a C-index of 0.713, exceeding the clinical model (0.651; P=0.012). Time-dependent AUCs at 1, 2, and 3 years were 0.760 (95%CI 0.651– 0.864), 0.838 (95%CI 0.736– 0.930), and 0.909 (95%CI 0.686– 1.000), whereas those of the clinical model were 0.676, 0.742, and 0.772. Kaplan–Meier analysis showed median OS of 9.5 vs 19.0 months for high- vs low-risk strata (HR 3.02, 95%CI 1.86– 4.91; P< 0.001). Discrimination was consistent across ten prespecified subgroups.
Conclusion: HepaKineticNet-derived ITH maps encode kinetic and spatial information that modestly improves individualized OS prediction and risk stratification in this combination-therapy HCC population, and may provide a noninvasive decision-support adjunct pending prospective validation. Keywords: radiomics, prognosis, prognostic model, risk stratification, convolutional neural network, immunotherapy, tyrosine kinase inhibitor, locoregional therapy, survival analysis
Journal IF-equivalent: 2.9 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Li J, Bu W, Hanming X, Zhang Q, Song J, Chen W. HepaKineticNet: Deep Learning of CT-Derived Intratumoral Heterogeneity for Overall Survival Prediction in BCLC Stage B-C Hepatocellular Carcinoma Treated with Locoregional Therapy Plus First-Line TKI and Anti–PD-1 Therapy. JHC. 2026 Oct;Volume 13:1-15. doi:10.2147/jhc.s636207.Checked: Abstract only - Abstract
Despite the widespread use of transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC), clinical outcomes vary substantially, and pretreatment tools for identifying patients at high risk of early progression remain limited. This study aimed to develop and externally validate an integrated CT-clinical model for predicting time to progression (TTP) after TACE. This retrospective multicenter study included 508 patients from three cohorts. The public WAW-TACE dataset ( \(n = 226\) ) was used for model development and was divided into a training cohort ( \(n = 158\) ) and an internal validation cohort ( \(n = 68\) ). Two institutional cohorts, cohort A ( \(n = 252\) ) and cohort B ( \(n = 30\) ), were used for independent external validation. Eligible patients had treatment-naive unresectable HCC treated with conventional TACE as the initial therapy, preserved liver function, no extrahepatic metastasis, no major vascular invasion, and available pretreatment contrast-enhanced CT. Clinical variables, radiomics features, and 2·5D deep learning features derived from arterial-phase CT were integrated to construct a time-to-progression prediction network (TTP-Net). TTP-Net achieved the highest observed performance among the compared models, achieving C-indices of 0.719, 0.723, 0.713, and 0.707 in the training cohort, internal validation cohort, external cohort A, and external cohort B, respectively. The corresponding 12-month AUCs were 0.872, 0.862, 0.816, and 0.832. Kaplan-Meier analysis showed significant separation between high-risk and low-risk groups in all four cohorts. Twelve-month decision-curve analysis further supported its potential clinical utility. Integration of pretreatment arterial-phase CT-derived imaging features and clinical variables enabled identification of patients with HCC at high risk of early progression after the first TACE session, supporting individualized surveillance planning and timely treatment reassessment after TACE.
Journal IF-equivalent: 5.3 (OpenAlex 2-year mean citedness, value as of 2026-10-02, retrieved 2026-10-03; not the official Clarivate IF)Reference: Wang L, Xia C, Peng Z, Zhao X, Wang Y, Wu Z, et al. Pretreatment arterial-phase CT-based prediction of time to progression after transarterial chemoembolization in hepatocellular carcinoma: a multicenter study. Cancer Imaging. 2026 Sep 30 [Epub ahead of print]. doi:10.1186/s40644-026-01136-3.Checked: Abstract only
Kidney cancer: treatment, trials and AI
No new qualifying paper for this issue.
Bladder cancer: treatment, trials and AI
No new qualifying paper for this issue.